Abstract
We thank Kasner for his comments on the Paracetamol (Acetaminophen) In Stroke (PAIS) trial.1 Kasner wondered whether the costs and efforts of a second study—aiming to confirm our post-hoc finding of a potential beneficial effect of high-dose paracetamol in patients with a baseline body temperature of 37·0°C to 39·0°C—will counterbalance the alleged small benefit of this treatment. Furthermore, he noted that there is sufficient evidence to prescribe paracetamol in patients with acute stroke and high body temperatures, and, therefore, this approach does not warrant further study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
